Communicable disease threats report, 8-14 July 2018, week 28
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 July 2018 and includes updates on carbapenemase-producing (OXA-48) Klebsiella pneumoniae, dengue, Ebola virus disease, poliomyelitis, MERS-CoV, mass gathering monitoring (FIFA Men's Football World Cup), measles, poliovirus type 2, rubella, Vibrio growth in the Baltic Sea, and West Nile virus.
Communicable Disease Threats Report, 3-9 June 2018, week 23
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 June 2018 and includes updates on dengue, Vibrio growth in the Baltic Sea, measles, rubella, hepatitis A, mass gathering monitoring, Carbapenem-resistant Enterobacteriaceae, Ebola virus disease, West Nile virus, polio and MERS-CoV.
- Carbapenem-resistant Enterobactericae
- Democratic Republic of the Congo
- Ebola haemorrhagic fever
- Ebola outbreak - North Kivu, Ituri, DRC
- Hepatitis A
- La Réunion
- Middle East respiratory syndrome coronavirus
- Public health threat
- West Nile virus infection
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
This document assesses the risk for patients and healthcare systems in the EU/EEA due to the global mcr-1 plasmid-mediated gene epidemic.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
US CDC report on antibiotic resistance threats in the United States, 2013
Antimicrobial resistance represent a serious threat to public health and patient safety and is a worldwide problem. Each year, in the European Union (EU) at least 25 000 patients die of infections with multidrug-resistant bacteria.